We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| CSL Limited | ASX:CSL | Australian Stock Exchange | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.19 | 2.07% | 255.46 | 255.31 | 255.60 | 255.92 | 249.22 | 249.58 | 1,452,095 | 07:50:00 |
From Mar 2022 to Mar 2025
By Josh Beckerman
Arcturus Therapeutics Holdings Inc. shares rose 26% to $23.10 after hours as the company announced a vaccine collaboration with CSL Ltd.'s CSL Seqirus.
Arcturus will receive $200 million upfront and is eligible to receive over $1.3 billion in development milestones and more than $3 billion in commercial milestones.
In addition, it is eligible to receive a 40% net profit share for Covid-19 vaccine products and up to double-digit royalties for certain other vaccines.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
November 01, 2022 19:12 ET (23:12 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year CSL Chart |
1 Month CSL Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
